JB/CALL/MODERNA/110/0.0333/21.03.25 | Market Closed - Bid/Ask 11:20:00 2024-06-14 am EDT | Pre-market 02:52:01 am | |||
| 1.4 CHF | -7.28% |
|
1.375 | -1.79% |
| Current month | -11.39% | ||
| 1 month | +26.13% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 1.4 | -7.28% |
| 24-06-12 | 1.51 | -4.43% |
| 24-06-11 | 1.58 | +3.27% |
| 24-06-10 | 1.53 | -8.38% |
| 24-06-07 | 1.67 | -6.18% |
Delayed Quote Swiss Exchange
Last update June 14, 2024 at 11:20 am EDT
More quotesStatic data
| Product type | Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | Bank Julius Bär |
| MRWOJB | |
| ISIN | CH1303723170 |
| Date issued | 2023-11-23 |
| Strike | 110 $ |
| Maturity | 2025-03-21 (278 Days) |
| Parity | 30 : 1 |
| Emission price | 0.4 CHF |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | CHF |
Technical Indicators
| Highest since issue | 2.12 CHF |
|---|---|
| Lowest since issue | 0.34 CHF |
| Delta | 0.79x |
| Omega | 2.384 |
| Premium | 11.63x |
| Gearing | 3.02x |
| Moneyness | 1.273 |
| Difference Strike | -30.03 $ |
| Difference Strike % | -27.30% |
| Spread | 0.01 CHF |
| Spread % | 0.72% |
| Theoretical value | 1.375 |
| Implied Volatility | 60.58 % |
| Total Loss Probability | 39.23 % |
| Intrinsic value | 0.8915 |
| Present value | 0.4835 |
| Break even | 156.31 CHF |
| Theta | -0.01x |
| Vega | 0.01x |
| Rho | 0.01x |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
140
USD
Average target price
145.2
USD
Spread / Average Target
+3.67%
- Stock Market
- Warrants
- MRWOJB Warrant
